KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Receivables (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Change in Receivables for 9 consecutive years, with $14.0 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Change in Receivables rose 264.34% year-over-year to $14.0 million, compared with a TTM value of $32.8 million through Mar 2025, up 174.79%, and an annual FY2025 reading of $36.8 million, up 62.16% over the prior year.
  • Change in Receivables was $14.0 million for Q1 2025 at Biocryst Pharmaceuticals, up from $7.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $14.0 million in Q1 2025 and bottomed at -$3.8 million in Q3 2023.
  • Average Change in Receivables over 3 years is $4.8 million, with a median of $3.8 million recorded in 2024.
  • Peak annual rise in Change in Receivables hit 290.14% in 2024, while the deepest fall reached 8.25% in 2024.
  • Year by year, Change in Receivables stood at $3.0 million in 2023, then surged by 145.66% to $7.3 million in 2024, then surged by 91.71% to $14.0 million in 2025.
  • Business Quant data shows Change in Receivables for BCRX at $14.0 million in Q1 2025, $7.3 million in Q4 2024, and $3.3 million in Q3 2024.